Physician Views: Gauging initial response to AstraZeneca's Saphnelo

Earlier this week, the FDA approved AstraZeneca's Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

Saphnelo is a first-in-class type I interferon (type I IFN) receptor antagonist and the first new treatment for SLE in more than 10 years. Its approval has been met enthusiastically by one key opinion leader (KOL) we spoke to this week.

To gauge how rheumatologists in general anticipate using Saphnelo, we are also running a snap-poll fielded with the following questions and will publish results and analysis next week…

  • How impressed have you been by the clinical data presented for Saphnelo from the Phase III TULIP-1 and TULIP-2 studies and the Phase II MUSE trial?
  • Do you intend to prescribe Saphnelo for the treatment of moderate-to-severe systemic lupus erythematosus (SLE)?
  • What percentage of moderate-to-severe SLE patients would you consider as potential candidates for treatment with Saphnelo at some stage in their disease management?
  • To approximately what percentage of moderate-to-severe SLE patients under your care do you currently prescribe Benlysta (belimumab) to?
  • At launch, would you consider Saphnelo a preferred treatment option over Benlysta in some patients?

Results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here.

To read more Physician Views articles, click here.